tbuckley/cabot-search huggingface dataset:
Ballade for Pancho Villa
Authors: Jack Coulehan
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book: Pocket PDR: Medical Book System
Authors: P. R Mills
Journal: BMJ (1999)

Franklin Electronic Publishers, $149.95 ISBN 1 56712 410 0 Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> It took me some time to work out what a “PDR” is, but, after rummaging through the literature that accompanied this palmtop device, I concluded that it probably stands for “Physicians' Desk Reference”. The Pocket PDR is essentially a personal digital assistant with medical information loaded on to it rather than the standard word processing and spreadsheet capabilities seen on the devices that increasing numbers of doctors wield on the wards on a daily basis. The medical information comes on “smart cards” that can be easily inserted and changed—I was provided … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif
Abstract 17965: Echocardiographic Assessment of Surgically Placed Melody Valves in the Mitral Position in Young Children
Authors: Lindsay R Freud, Sitaram M Emani, Audrey C Marshall, Gerald R Marx, Wayne Tworetzky
Journal: Circulation (2014)

Introduction: Mitral valve replacement (MVR) in young children is limited by lack of small prostheses, resulting in high re-intervention rates and mortality. Therefore, in 2010, we began performing MVR with modified, surgically placed, stented jugular vein grafts (Melody valve) to allow for tailoring to small annular dimensions as well as subsequent expansion in the catheterization lab. We aimed to analyze key pre- and post-operative (op) echo variables to refine surgical planning for this novel procedure. Methods: We included 17 patients who underwent surgically placed Melody MVR. The pre- and post-op echoes before discharge were retrospectively reviewed for anatomic and physiologic variables. On the pre-op echo, we performed “potential” mitral annular measurements in orthogonal planes to estimate the maximum intra-op balloon sizing. Given concern for left ventricular outflow tract obstruction (LVOTO), a ratio of the narrowest subaortic region in systole to the actual mitral annular dimension (SubA:MV) was assessed in the parasternal long axis view. Values are presented as median (range), where applicable. Results: Melody MVR was performed at 8 months of age (weight 5.2 kg) for stenosis (5), regurgitation (1), and mixed disease (11). On pre-op echo, the potential mitral measurement in the lateral dimension correlated well with the intra-op balloon size selected by the surgeon (ρ=0.58, p=0.01). The Melody valve was expanded to 1.0 times the potential lateral dimension (median 14 mm). The SubA:MV measured &gt;0.5 in all patients. By post-op day 10 (5-35), the mean mitral gradient improved by 9 mm Hg (1-16), and right ventricular pressure was &lt;½ systemic in 76% (vs. 12% pre-op, p&lt;0.001). Only 2 patients had mild regurgitation and 1 had a mild perivalvar leak. The internal diameter of the Melody valve measured 3.4 mm (1-6) less than the intra-op balloon size. No patient had LVOTO &gt;25 mm Hg or pulmonary vein obstruction. Conclusion: Intra-op balloon sizing of Melody MVR may be guided by pre-op echo indices to achieve adequate mitral valve function without significant LVOTO. The post-op Melody valve diameter was found to measure less than the intra-op balloon size, which should be considered as experience with the Melody in native, non-conduit positions evolves.
Abstract 15209: Effects of Coffee Consumption on Exercise Tolerance, Blood Pressure, Heart Rate, Heart Rate Variability and Premature Beats in Volunteers with Coronary Artery Disease
Authors: Bruno M Mioto, Miguel A Moretti, Daniela Tarasoutchi, Reynaldo V Amato, Dante M Giorgi, César J Grupi, Luiz A Machado César
Journal: Circulation (2014)

Introduction: Coffee is supposed to increase blood pressure (BP) and heart rate (HR), which may be deleterious for patients with coronary artery disease (CAD). However a review of the literature reveals few studies evaluating these effects in patients with CAD. Objective: The aim of this study was to compare the effects of dark roast (DR) and medium dark roast (MDR) paper-filtered coffee on BP, exercise tolerance, HR, heart rate variability (HRV) and extrasystoles in volunteers with CAD. Methods: This randomized crossed-over trial compared the effects of consuming three or four cups (150 mL) of DR and MDR coffee per day for 4 weeks in 40 volunteers with CAD. In the baseline and after each 4 weeks period of drinking they were submitted to treadmill test, ambulatory blood pressure monitoring (24-h ABPM) and 24-h Holter ECG. We analyzed average systolic BP (SBP) and diastolic BP (DBP) at 24-h ABPM, total exercise time ([[Unable to Display Character: &amp;#8710;]]T Exercise) and double product (DP) at treadmill test, and average HR, SDNN, ventricular (VPB) and supraventricular premature beats (SPB) at 24-h Holter ECG. Variables were evaluated by ANOVA for repeated measures and Friedman test when indicated. Results: We evaluated 40 subjects with CAD, 64.7 ± 6.7 years old, 32 men. All volunteers received adequate treatment for CAD according to the guidelines. Compared with baseline, subjects had an increase of 6.4% and 5.7% in [[Unable to Display Character: &amp;#8710;]]T exercise at treadmill test after MDR and DR consumption respectively [565.8 ± 194.8 vs 601.8 ± 212.9 vs 597.8 ± 208.0 s (p=0.001)] without an increase in DP (p=0.91). In the 24-h Holter ECG at baseline, DR and MDR the following values were obtained, respectively: HR [67.1 ± 8.6 vs 66.5 ± 8.2 vs 67.2 ± 8.5 (p=0.71)], SDNN [130.6 ± 32.7 vs 134.2 ± 30.6 vs 129.7 ± 28.5 (p=0.428)], VPB [8.0 (2.0-395.5) vs 9.5 (0.2-54.7) vs 11.5 (3.0-51.7) (p=0.16)] and SPB [18.0 (5.2-73.0) vs 20.0 (5.5-75.5) vs 16.5 (6.2-72.5) (p=0.52)]. In the 24-h ABPM at baseline, DR and MDR the following values were obtained, respectively: SBP [110.8 ± 9.1 vs 109.2 ± 19.9 vs 114.7 ± 11.8 mmHg (p=0.10)] and DBP [64.1 ± 9.1 vs 64.6 ± 9.3 vs 66.4 ± 9.7 mmHg (p=0.14)]. Conclusions: Paper-filtered coffee increased exercise tolerance and had no considerable effect on BP, HR, HRV and premature beats in volunteers with CAD.
Abstract 130: PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models
Authors: Luc Friboulet, Helen Zou, David P. Kodack, Lars D. Engstrom, Qiuhua Li, Melissa West, Ruth W. Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang, Sergei Timofeevski, Dac M. Dinh, Hieu Lam, Justine L. Lam, Shinji Yamazaki, Wenyue Hu, Bhushankumar Patel, Divya Bezwada, Sidra Mahmood, Eugene Lifshits, Timothy Affolter, Patrick B. Lappin, Hovhannes Gukasyan, Nathan Lee, Shibing Deng, Rakesh K. Jain, Ted W. Johnson, Alice T. Shaw, Valeria R. Fantin, Tod Smeal
Journal: Cancer Research (2015)

Abstract Overcoming resistance to targeted kinase inhibitors is a major clinical challenge in oncology. For 1st and 2nd generation ALK inhibitors acquired resistance due to ALK kinase domain mutations and/or pharmacological drug resistance are major causes for disease relapse. Here, we report the preclinical evaluation of PF-06463922, a potent and brain penetrant ALK/ROS1 inhibitor with sub to low nanomolar cell potency against ALK fusions and all known clinically-acquired resistant mutations. PF-06463922 exhibited marked cytoreductive activity in tumor xenografts driven by various ALK mutants. Furthermore, PF-06463922 led to significant regression of EML4-ALK driven lung cancer brain metastasis and prolonged mouse survival. Compared to other clinically available ALK inhibitors, PF-06463922 is unique in its superior potency against a broad spectrum of acquired ALK mutations, including the highly resistant G1202R mutant and its robust antitumor activity in the brain. Furthermore, PF-06463922 demonstrated remarkable selectivity and safety margins in a variety of preclinical studies. These results suggest that PF-06463922 may be highly effective for the treatment of patients with ALK-driven lung cancers, including those who relapsed on clinically available ALK inhibitors due to ALK secondary mutations and/or brain metastases. Citation Format: Luc Friboulet, Helen Zou, David P. Kodack, Lars D. Engstrom, Qiuhua Li, Melissa West, Ruth W. Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang, Sergei Timofeevski, Dac M. Dinh, Hieu Lam, Justine L. Lam, Shinji Yamazaki, Wenyue Hu, Bhushankumar Patel, Divya Bezwada, Sidra Mahmood, Eugene Lifshits, Timothy Affolter, Patrick B. Lappin, Hovhannes Gukasyan, Nathan Lee, Shibing Deng, Rakesh K. Jain, Ted W. Johnson, Alice T. Shaw, Valeria R. Fantin, Tod Smeal. PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 130. doi:10.1158/1538-7445.AM2015-130
COPD patients' expectations of ICS/LABA therapy
Authors: Juliet Foster, Christine Jenkins, Brett Toelle, Lorraine Smith, Helen Reddel
Journal: European Respiratory Journal (2014)

Introduction : Guidelines recommend inhaled corticosteroid/long acting β 2 -agonist (ICS/LABA) for severe COPD yet little is known about patients9 expectations of these treatments.  Aim : To describe patients9 expectations and attitudes toward ICS/LABA.  Methods : Patients aged ≥40 years with a self-reported doctor diagnosis of COPD, >10 pack smoking years and prescribed ICS/LABA for COPD for ≥3 months completed a survey about their expectations and attitudes.  Results : In 137 patients (mean age 69±11 yrs; 56% male; CAT score 20.5±12, MRC dyspnoea grades: 0:15%, 1:44%, 2:26%, 3:14%, 4:1%) the most common reasons patients reported their Doctor (Dr) gave for taking ICS/LABA were: assist/improve breathing (67%), maintain/slow disease progression (9%) and increase physical activity (2%). 48% of patients had their own personal reasons for taking ICS/LABA; the most commonly reported were assist/improve breathing (26%), follow Dr9s orders (11%) and improve quality of life (9%). Patients9 ratings of how well ICS/LABA works (0=hasn9t worked, 10=worked extremely well) were moderately high for both Dr reasons for taking ICS/LABA (7.4±2.3) and patient reasons (7.8±2.3). Patients reported that shortness of breath, difficulty exercising and breathing test results would be better with (and worse without) ICS/LABA. Self-reported adherence was high (90% of prescribed dose) and did not differ between those with and without a personal reason for taking ICS/LABA (p=0.140).  Conclusion : Half of COPD patients have personal reasons for taking ICS/LABA which they consider different from their Dr9s. Despite this, their expectations of ICS/LABA appear to be met, and self-reported adherence is high although objective adherence assessment is needed to confirm this.
Abstract P5-05-10: Leptin peptide receptor antagonist linked to nanoparticles: A novel adjuvant therapy for triple negative breast cancer
Authors: Tia L Harmon, Adriana Harbuzariu, Courtney D Dill, Lily Yang, Ruben R Gonzalez-Perez
Journal: Cancer Research (2015)

Abstract Background: Obesity and high leptin levels are strongly associated with breast cancer, relapse, drug resistance, and poor patient outcomes. Over expression of leptin and its receptor, Ob-R, induce cell proliferation, angiogenesis, and metastasis in Triple Negative Breast Cancer (TNBC). This aggressive form of the disease has no targeted therapy and chemotherapeutics show several undesirable side effects. We have created a Leptin Peptide Receptor Antagonist, LPrA2, which has been shown to effectively prevent leptin signaling. LPrA2 was coupled to iron oxide nanoparticles (IONPs) and used to determine its potential use as an adjuvant to chemotherapeutics. Methods: IONPs, bound to LPrA2, were confirmed by Western Blot. TNBC cells were then treated with IONP-LPrA2 plus Cisplatin, Doxorubicin, Paclitaxel, Cyclophosphamide, and Sunitinib. Subsequently, the TNBC cells were analyzed for proliferation, cell cycle progression, and apoptosis with the Cellometer Vision Image Cytometer ®. Results: IONP-LPrA2 was found to cause a greater decrease in DNA synthesis during the S phase of the cell cycle in TNBC cells than LPrA2 alone. Additionally, IONP-LPrA2 when combined with chemotherapeutics or anti-angiogenic drugs showed synergistic effects on cell proliferation and apoptosis. Conclusion: These findings indicate that IONP-LPrA2 may be useful in the prevention and treatment of TNBC. Further IONP-LPrA2 treatment may increase the efficiency of chemotherapeutics. These results could be particularly relevant for obese patients, whom show high incidence and the poorest outcome of TNBC. Acknowledgements: This work was partially supported by the National Institutes of Health and National Cancer Institute Grant 1SC1CA138658-05 and U54 CA118638, and DOD Idea Award BC 123427 to RRGP; and facilities, and support services at Morehouse School of Medicine (NIH RR03034 and 1C06 RR18386) and NIH/NCRR grant 1G12RR026250-03. Citation Format: Tia L Harmon, Adriana Harbuzariu, Courtney D Dill, Lily Yang, Ruben R Gonzalez-Perez. Leptin peptide receptor antagonist linked to nanoparticles: A novel adjuvant therapy for triple negative breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P5-05-10.
Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis
Authors: J. Romaní, A. Caixàs, J.M. Carrascosa, M. Ribera, M. Rigla, J. Luelmo
Journal: British Journal of Dermatology (2012)

Previous studies have shown increased prevalence of metabolic syndrome in patients with psoriasis.To characterize the anthropometric and metabolic profile of Spanish patients with moderate to severe psoriasis compared with controls without psoriasis matched for gender, age and body mass index (BMI), and to evaluate the impact of narrowband ultraviolet B (NB-UVB) therapy on patient profiles.Baseline waist circumference, body fat composition, lipid, carbohydrate and calcium metabolism profile, inflammation markers, homocysteine, vitamins D, B(6) and B(12) and folic acid of 50 patients with psoriasis and 50 matched controls were recorded then evaluated after NB-UVB in patients with psoriasis and correlated with clinical outcome.Despite very similar BMIs, 54% of patients met International Diabetes Foundation criteria for metabolic syndrome compared with 42% of controls (P = 0·01); body fat was 29·9% in patients and 28·0% in controls (P = 0·037), correlating with waist circumference; while patient atherogenic profiles were less favourable, with higher apolipoprotein B and low density lipoprotein cholesterol than controls, and both patients and controls showed insufficient vitamin D serum levels (< 20 ng mL(-1)). Mean improvement of Psoriasis Area and Severity Index (PASI) after NB-UVB was 78·2%. Ferritin, B(12) and C-reactive protein decreased significantly after NB-UVB therapy. Vitamin D levels reached adequate levels after phototherapy; however, no relationship with PASI improvement was observed.We characterized inflammatory and atherogenic profiles of Spanish patients with psoriasis compared with matched controls. After NB-UVB therapy we demonstrated improvement in psoriasis and some systemic inflammation markers, which were not mediated by enhancement of vitamin D synthesis.
Abstract P015: Fibroblast Growth Factor 23 and Echocardiographic Measures of Cardiac Structure and Function among African Americans: The Atherosclerosis Risk in Communities (ARIC) Study
Authors: Jeffrey R Misialek, Alvaro Alonso, Erin D Michos, Scott D Solomon, Amil M Shah, Suma Konety, Sunil K Agarwal, Elizabeth Selvin, Pamela L Lutsey
Journal: Circulation (2014)

Introduction: Fibroblast growth factor 23 (FGF23), an endocrine hormone, induced left ventricular (LV) hypertrophy through direct action in experimental animal models. The association of FGF23 with echocardiographic measures in humans is relatively uncharacterized. Hypothesis: Higher levels of FGF23 will be cross-sectionally associated with more adverse echocardiographic measures of LV structure and function. Methods: We conducted a cross-sectional analysis of 2086 African-American adults (66% female, median age 55) from a subset of the ARIC Study, a community-based cohort in the United States. Intact active FGF23 was assessed in blood samples collected at ARIC visit two (1990-1992). Echocardiography was performed at visit three (1993-1995) in participants recruited at the Jackson field center only. We used multivariable linear regression to evaluate the associations of FGF23 (per 15 pg/mL change) with echocardiographic measures after adjustment for traditional cardiovascular risk factors assessed at visit two. We also examined differences in observed associations by age and sex using interaction terms. Results: FGF23 was significantly associated with greater left atrial diameter and LV mass index (Table). A significant sex interaction was identified for LV diameter (p-interaction = 0.005). No association was observed in men while a positive association was observed among women. An adverse, decreasing trend in percent fractional shortening of the LV diameter at higher levels of FGF was stronger in individuals aged &gt;55 (p-interaction = 0.03). No linear association was found between FGF23 and E/A ratio. Conclusion: FGF23 was associated with higher LV mass, larger LV size, and lower LV systolic function. These findings are consistent with results from experimental animal studies and provide evidence suggesting that cardiac structure and function may be influenced by FGF23 in humans. Prospective studies are needed to evaluate whether FGF23 is associated with change in markers of cardiac structure and function.
169. Intrapancreatic Injections of Adeno-Associated Virus Vectors for Local Gene Expression
Authors: Scott A. Loiler, Qiushi Tang, Marcel Perret-Gentil, Martha L. Campbell-Thompson, Mark A. Atkinson, Terence R. Flotte
Journal: Molecular Therapy (2004)

Gene transfer into human pancreatic islet cells could be of therapeutic importance either ex vivo by prolonging survival of islet cell allografts in type I diabetes or in vivo by interrupting the progression of autoimmunity in susceptible individuals. Recombinant adeno-associated virus vectors (rAAV) may hold promise for gene therapy of diabetes, since gene expression is long-lasting and the vector elicits little inflammatory response. Previously we have shown that a single intramuscular injection of rAAV/IL-10 produce systemic IL-10 expression that prevents the development of type 1 diabetes in NOD mice1. In an effort to limit the biodistribution we have adapted a clinically relevant surgical technique to efficiently deliver rAAV vectors directly to the pancreas. In a procedure similar to endoscopic retrograde cholangiopancreatography (ERCP) we have delivered rAAV encoding human alpha-1-antitrypsin (hAAT) to the pancreas of three-week-old Fischer rats. We compared different natural as well as bioengineered serotypes of AAV (AAV1, AAV2/Apo2, AAV8) as well as different promoters (chicken β-actin, human insulin) in vivo. Three weeks post-injection AAV1 vectors show the highest serum concentration of hAAT expression (week 2, AAV1/CB-AT, 579 ± 457 ng/ml). The chicken β-actin promoter gave the highest expression early but was sharply reduced by week three (579 ± 457 ng/ml vs. 9 ± 42 ng/ml). Preliminary immunohistochemical staining indicates transduction of both acinar and beta cells of the pancreas with the AAV1/CB-AT vector. Serum amylase and glucose levels were normal throughout the study and minimal if any pancreatitis was observed during necropsy or by histopathology. We are in the process of evaluating the serum for the presence of anti-hAAT antibodies to see if that is the cause of the week 3 reduction in expression as well as repeating the experiment in C57/black6 mice that are tolerant to hAAT expression.
Correlates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide
Authors: Ajay J. Kirtane, Gregory Piazza, Sabina A. Murphy, Daniela Budiu, David A. Morrow, David J. Cohen, Eric Peterson, Nasser Lakkis, Howard C. Herrmann, Theresa M. Palabrica, C. Michael Gibson
Journal: Journal of the American College of Cardiology (2006)
Reorganisation proposed for NHS in Northern Ireland
Authors: Doug Payne
Journal: BMJ (2001)

Sweeping changes have been proposed for Northern Ireland's hospitals in a report on the province's acute care system.

Presented as “a route map-not a blueprint” by the former ombudsman for Northern Ireland, Maurice Hayes, the 136 page plan calls for capital expenditure of £1bn ($1.4bn), a doubling of the number of consultants, a 25% increase in the number of GPs, and a 20% boost in nursing staff.

In the first major shake-up of the area's health services in a …
A new gene, encoding an anion transporter, is mutated in sialic acid storage diseases
Authors: Frans W. Verheijen, Elly Verbeek, Nina Aula, Cecile E.M.T. Beerens, Adrie C. Havelaar, Marijke Joosse, Leena Peltonen, Pertti Aula, Hans Galjaard, Peter J. van der Spek, Grazia M.S. Mancini
Journal: Nature Genetics (1999)